Moderna generated total revenues of some 3.2 billion U.S. dollars in 2024, a massive decrease compared to the years before. The drop was mainly due to the decreasing demand for its COVID-19 vaccine Spikevax. Working hard to produce the first 'blockbuster' Moderna is a clinical stage biotech company that is pioneering messenger RNA (mRNA) therapeutics and vaccines. Beside its COVID-19 vaccine, the company is yet to generate revenues from the sale of potential drugs, and this will remain the same until it successfully completes clinical development and obtains regulatory approval for one of its medicines. Like many other biotech companies, Moderna invests significant amounts of money into research and development projects, and annual costs continue to grow. One of the very first COVID-19 vaccines approved Moderna, in partnership with the National Institutes of Health (NIH) and the Coalition for Epidemic Preparedness Innovations (CEPI), was one of the very first to develop a vaccine to fight COVID-19. The vaccine codenamed mRNA-1273 – designed and manufactured in only 25 days – prevents future infections of the novel coronavirus that has caused the pandemic. The Moderna vaccine successfully went through all necessaryclinical phases, and was the second vaccine - after the Biontech/Pfizer vaccine - to be approved for widely usage already in late 2020.

In 2023, Moderna Inc.'s collaboration revenue with partner Vertex amounted to 82 million U.S. dollars. Moderna became widely known for being one of two companies worldwide which had their COVID-19 vaccines approved already in late 2020.

Moderna reported $-1120000000 in Net Income for its fiscal quarter ending in December of 2024. Data for Moderna | MRNA - Net Income including historical, tables and charts were last updated by Trading Economics this last March in 2025.

Moderna's annual revenue was $3.24B in fiscal year 2024. The annual revenue decreased -$3.61B from $6.85B (in 2023) to $3.24B (in 2024), representing a -52.75% year-over-year decline.

This statistic illustrates the annual net loss of Moderna Inc. from 2016 to 2023. Moderna became well-known for developing one of the very first COVID-19 vaccines to be approved for widely usage in 2020. After the two very successful years 2021 and 2022, the company recorded a net loss of 4.7 billion U.S. dollars in 2023.

In fiscal year 2024, Moderna's revenue by geographical region are as follows: Europe: $598.00M, Rest Of The World: $810.00M, UNITED STATES: $1.79B.

In fiscal year 2024, the revenue per employee at Moderna was $557.93K. The revenue per employee decreased by $664.93K from $1.22M (in 2023) to $557.93K (in 2024).

The revenue of Moderna with headquarters in the United States amounted to 6.8 billion U.S. dollars in 2023. The reported fiscal year ends on December 31.Compared to the earliest depicted value from 2019 this is a total increase by approximately 6.8 billion U.S. dollars. The trend from 2019 to 2023 shows, however, that this increase did not happen continuously.

Moderna experiences a substantial financial loss in Q4 2024, with vaccine sales underperforming amid global market challenges.

Moderna reported $12.52B in Market Capitalization this March of 2025, considering the latest stock price and the number of outstanding shares.Data for Moderna | MRNA - Market Capitalization including historical, tables and charts were last updated by Trading Economics this last March in 2025.

Moderna reported 35.86 in PE Price to Earnings for its fiscal quarter ending in September of 2024. Data for Moderna | MRNA - PE Price to Earnings including historical, tables and charts were last updated by Trading Economics this last March in 2025.

Moderna stock price, live market quote, shares value, historical data, intraday chart, earnings per share and news.

According to a forecast as of March, BioNTech's and Pfizer's vaccine against COVID-19 could generate sales revenues of nearly 22 billion U.S. dollars during 2021. The BioNTech/Pfizer vaccine was the first COVID-19 vaccine to be widely approved and used. German biotech company BioNTech saw a 156 percent growth in its shares in the last 12 months as of March 2021.

Will Moderna be the big winner? Moderna is expected to be the company with the largest sales revenues from a COVID-19 vaccine. Forecasts predict that the company will make around 43 billion U.S. dollars in sales through its vaccine. Interestingly, Moderna was established in 2010 and had never made profit before the pandemic. Thus, the development of the covid vaccine based on the latest mRNA technology will mark a definitive breakthrough for the Massachusetts-based biotech company. Moderna received significant funding through taxpayer money as well as help in research and development from the National Institutes of Health.

Vaccine pricing in a pandemic Drug pricing is always a big issue and this was also the case with COVID-19 vaccines. While some companies, like AstraZeneca, stated early on that prices for the vaccine will be on a non-profit base at least as long as the pandemic is ongoing, others took a more profit-oriented approach. However, even these companies state that their current prices are low special prices, taking into account urgent public health interests, which normally would be much higher. According to several projections, COVID-19 drugs and vaccines could establish a market worth some 40 billion U.S. dollars annually.

This dataset is about companies and is filtered where the company includes Moderna, featuring 5 columns: city, company, country, foundation year, and revenues. The preview is ordered by revenues (descending).

Moderna reported $-1246000000 in EBIT for its fiscal quarter ending in December of 2024. Data for Moderna | MRNA - Ebit including historical, tables and charts were last updated by Trading Economics this last March in 2025.

As of September 6, 2021, high-income countries accounted for around 84 percent of total Moderna vaccines delivered worldwide. Moderna delivered none of its vaccines to low-income countries, at all. The statistic illustrates the share of Moderna COVID-19 vaccines delivered worldwide, by country income group.

Moderna reported $38.6K in Ordinary Share Capital for its fiscal quarter ending in December of 2024. Data for Moderna | MRNA - Ordinary Share Capital including historical, tables and charts were last updated by Trading Economics this last March in 2025.

In 2020, U.S. mRNA specialist Moderna reported a net loss of around 750 million U.S. dollars. Two years later, and thanks to the success of its COVID-19 vaccine Spikevax, it was around 8.4 billion U.S. dollars.

The use of mRNA as a drug takes a fundamentally different approach to treating diseases than other drug classes. mRNA is the instruction that cells in the human body use to make proteins and send them to various locations in the body. mRNA drugs make use of normal biological processes to create proteins and achieve the desired therapeutic effect. This enables the potential treatment of a wide variety of diseases, many of which cannot be treated with current technologies.

The operating profit of Moderna with headquarters in the United States amounted to -4,239 million U.S. dollars in 2023. The reported fiscal year ends on December 31.Compared to the earliest depicted value from 2019 this is a total decrease by approximately 3.7 billion U.S. dollars. The trend from 2019 to 2023 shows, however, that this decrease did not happen continuously.

Moderna reported $117M in Stock for its fiscal quarter ending in December of 2024. Data for Moderna | MRNA - Stock including historical, tables and charts were last updated by Trading Economics this last March in 2025.